We just received data on a new analyst forecast for $SRPT. Brian Skorney from Baird set a price target of 35.0 for SRPT.

Deep-pocketed investors have adopted a bullish approach towards Sarepta Therapeutics (NASDAQ:SRPT), and it's something market players shouldn't ignore. Our tracking of public options records at ...

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Sarepta Therapeutics Inc (Symbol: SRPT), where a total of 115,596 contracts have traded ...

CAMBRIDGE, Mass. -- (BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the following statement: Shortly after 2:30 ...

Sarepta plummets after a third death in its muscular dystrophy program for investigational gene therapies, prompts FDA action and intensifies safety scrutiny.

SRPT Slides on Voluntary US Elevidys Shipment Pause Amid Scrutiny July 22, 2025 — 09:33 am EDT Written by Zacks Equity Research for Zacks -> ...

The NASDAQ 100 Pre-Market Indicator is up 25.99 to 23,107.04. The total Pre-Market volume is currently 137,099,362 shares traded.The following are the most active stocks for the pre-market session ...

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sarepta investors who were adversely affected by alleged securities fraud between June 22, 2023 and June 24, 2025. Follow the link ...

$260,000 of SAREPTA THERAPEUTICS INC. lobbying was just disclosed, from Q2 of 2025, in a new Lobbying Disclosure Act filing.

(RTTNews) - Sarepta Therapeutics, Inc. (SRPT), Friday acknowledged the Committee for Medicinal Products for Human Use's negative opinion on the conditional marketing authorization for ELEVIDYS in ...

We recently published 11 Stocks That Jim Cramer Recently Talked About. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is one of the stocks Jim Cramer recently discussed. Sarepta Therapeutics, Inc.